AT-401

N/A

Report date: 2025/05/26 10:52:18

Base Information

Drug NameAT-401
Drug Alias NameAT-401
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsReceptor protein-tyrosine kinase erbB-2 modulators
TargetsB-lymphocyte antigen CD20Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesA28 Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesA28 Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A